Currently, it is estimated that the United States embolic protection device market is worth $50M based on a TAVR population of 95,000 patients . By 2030, it is expected that embolic protection devices will be worth $400M, an eightfold increase. Meanwhile, we expect to launch our device after regulatory clearance in the year 2025, when the United States TAVR population is projected to be at 229,000 patients .
We believe our device can benefit nearly 60,000 patients by the year 2030, and present a safer and easier alternative to the SENTINEL device as well as other embolic protection devices. In the first five years after obtaining regulatory approval, this translates to $128M in sales (assuming a competitive price of $2,200 per ArchGuard device). After reaching our 15% adoption milestone, our net margin of 52% will translate to an average profit of $6.7M per year.
- “United Nations Population Division | Department of Economic and Social Affairs.” United Nations, United Nations.
- De Sciscio, Paolo, et al. “Quantifying the Shift Toward Transcatheter Aortic Valve Replacement in Low-Risk Patients: A Meta-Analysis.” Circulation: Cardiovascular Quality and Outcomes, 2017.